Jasper Kunow is Managing Director for the Central Eastern European countries, namely Poland, Hungary, Czech Republic, and Slovakia. Jasper is a member of the MSD Leadership Team for Mid-Europe.
In parallel, Jasper serves as country champion for Poland at the EFPIA (European Federation of Pharmaceutical Industries and Associations) CEE Task Force.
Jasper joined MSD in 2014. In his previous role, he stood up and led the Oncology organization in mid-Europe. In this capacity, Jasper was tasked with leading the regional Oncology team to develop and coherently execute the strategy for MSD’s anti-PD-1 medicine.
His team, in close collaboration with the Medical Affairs, Market Access and Policy functions, succeeded in propelling KEYTRUDA into the leadership position within the pharmaceutical market, thereby touching the lives of about 70’000 cancer patients in need since first launch within the region.
From 2003 to 2014, Jasper held various international leadership positions at F. Hoffmann–La Roche Ltd, including Global Launch Readiness Lead across multiple therapeutic areas, such as Oncology, Neuroscience, Cardiometabolic Diseases, and Immunology, as well as Commercial Biosimilars Task Force Lead. Before that, he served as Global Commercial Lead for Herceptin. In addition to designing the growth strategy, Jasper supported the clinical development of the Herceptin subcutaneous formulation plus additional innovative HER2-targeted anticancer medicines including Perjeta and Kadcyla.
Jasper’s 25-year career in the pharmaceutical industry has spanned several positions and three companies. From 1995 till 2002, Jasper held several sales, marketing and commercial operations roles at Bristol-Myers Squibb GmbH as well as Hoffmann-La Roche AG.
Jasper holds a diploma degree in biology, and a doctorate in micro- & molecular biology from Philipps-University Marburg, Germany.